Microcap Ledger Actinium Pharmaceuticals, Inc. $ATNM
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Pharmaceutical Preparations
- Headquarters
- New York, NY
- Fiscal year end
- December 31
- Shares outstanding
- 31,441,436 [10-Q 2026-08-07]
What the company doesAI summary of filing
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted radiotherapies for oncology. The company is focused on radiopharmaceutical therapeutics targeting novel antigens in solid tumors and hematologic malignancies, with programs in prostate cancer, non-small cell lung cancer, breast cancer, acute myeloid leukemia, and myelodysplastic syndrome. The company is pre-revenue and generates no current revenue; it finances operations through capital raises. Actinium's pipeline includes ATNM-400 and Actimab-A for solid tumors, Actimab-A for hematologic malignancies in partnership with the National Cancer Institute, and Iomab-B and Iomab-ACT for bone marrow transplant and cell and gene therapy conditioning. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $35.00M | $22.38M | −$11.05M | $36.47M | [10-Q 2026-08-07] |
| FY ended Dec 2025 | $90.0K | −$33.89M | −$24.58M | $48.00M | [10-K 2026-03-30] |
| FY ended Dec 2024 | — | −$38.24M | −$33.07M | $72.90M | [10-K 2026-03-30] |
- Quarterly cash burn
- −$5.52M
- Cash runway Estimate
- ~19.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-14 | 31,195,891 | [10-Q 2024-11-14] |
| 2025-03-28 | 31,195,891 | [10-K 2025-03-31] |
| 2025-05-09 | 31,195,891 | [10-Q 2025-05-09] |
| 2025-08-08 | 31,195,891 | [10-Q 2025-08-08] |
| 2025-11-14 | 31,195,891 | [10-Q 2025-11-14] |
| 2026-03-30 | 31,374,994 | [10-K 2026-03-30] |
| 2026-05-07 | 31,374,991 | [10-Q 2026-05-08] |
| 2026-08-06 | 31,441,436 | [10-Q 2026-08-07] |
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-14. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-08-14 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-14] |
| 2026-05-29 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-05-29] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-02 | Shetty Ajit | grant | 61,600 | — | [4 2026-09-04] |
| 2026-09-02 | Nicholson, C. David | grant | 62,800 | — | [4 2026-09-04] |
| 2026-09-02 | Almenoff June Sherie | grant | 18,000 | — | [4 2026-09-04] |
| 2026-09-02 | Seth Sandesh | grant | 753,600 | — | [4 2026-09-04] |
| 2026-09-02 | Seth Sandesh | grant | 1,027,274 | — | [4 2026-09-04] |
| 2026-09-02 | Steinhart Richard I | grant | 62,800 | — | [4 2026-09-04] |
| 2026-09-02 | Chell Jeffrey W. | grant | 61,600 | — | [4 2026-09-04] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 8-K | Listing notice or transfer; Regulation FD disclosure |
| 2026-08-07 | 10-Q | Quarterly report |
| 2026-06-18 | 8-K | Other events |
| 2026-05-29 | 8-K | Listing notice or transfer; Regulation FD disclosure |
| 2026-05-08 | 10-Q | Quarterly report |
| 2026-03-30 | 10-K | Annual report |
| 2026-03-26 | 8-K | Shareholder vote results |
| 2026-02-13 | 8-K | Director or officer change |
| 2025-11-26 | 8-K | Director or officer change; Shareholder vote results |
| 2025-11-14 | 10-Q | Quarterly report |
| 2025-11-05 | DEF 14A | Proxy statement |
Alerts for $ATNM
Email me when Actinium Pharmaceuticals, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.